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Expression of NOD2/CARD15 in the Paneth cell may be critical in
the pathogenesis of Crohn’s disease
T
he emergence and application of
novel molecular techniques over
the last decade has provided a
needed catalyst to studies of the patho-
genesis of the chronic inflammatory
bowel diseases (IBD): Crohn’s disease
(CD) and ulcerative colitis (UC).
Successful development of genetically
engineered models of intestinal inflam-
mation has not only provided insight
into the dysregulation of the mucosal
immune system characteristic of IBD
but has also emphasised the critical and
complex role of the bacterial flora in
establishing and maintaining chronic
intestinal inflammation.1 These
advances in understanding pathophy-
siology in turn have already led to novel
therapeutic approaches.2 3
However, it is in studies of human
genetics that landmark progress has
been made, widely recognised not only
within gastroenterology but also by
investigators in all complex diseases.4
Genome wide scanning led initially to
the identification of a number of sus-
ceptibility loci, the statistical evidence
for which satisfy stringent criteria for
definite linkage.5 The subsequent detec-
tion of the NOD2/CARD15 gene6–8
within the IBD1 linkage interval and
the association of mutations within this
gene with susceptibility to CD is widely
regarded as the most stringent proof of
principle for hypothesis free genome
scanning in complex diseases.
In the time that has elapsed since the
discovery of NOD2/CARD15, the contri-
bution of this gene in determining
susceptibility and disease behaviour in
IBD has received detailed examination.
It is now clear that NOD2/CARD15
mutations are associated with suscept-
ibility to CD but not UC.6 However, the
contribution is subject to considerable
ethnic and even regional variation.
Whereas mutations may be carried by
up to 50% of central Europeans with
CD,9 these mutations are not present in
Japanese10 or Afro-American11 patients.
Even within Europe, there is consider-
able regional variation12–15 and reported
population attributable risks vary from
7.1% to 32%. Furthermore, there is
heterogeneity within CD, and geno-
type-phenotype relationships clearly
exist. Independent data suggest that
NOD2/CARD15 variants are associated
with early onset disease,9 11 involvement
of the terminal ileum,16 17 and fibro-
stenosing disease,18 all phenotypic char-
acteristics initially implicated in Crohn’s
initial descriptions of regional enteritis.19
The most intriguing question that
remains to be answered concerns the
mechanism whereby mutations in the
NOD2/CARD15 gene predispose towards
the chronic intestinal inflammation
characteristic of CD. Studies with
respect to protein structure, expression,
and function promise to provide the
answers but the critical questions
remain unresolved. The NOD2/CARD15
gene, initially described by Ogura and
colleagues,20 encodes a 1040 amino acid
protein, a member of the Apaf1/CARD
family of cytosolic proteins, involved in
apoptosis (programmed cell death).
NOD2/CARD15 has sequence homology
with other family members,21 notably
NOD1/CARD4, which itself is not asso-
ciated with CD susceptibility.22 The
gene comprises two N terminal caspase
activation and recruitment domains
(CARD), a nucleotide binding domain,
and a C terminal sequence of leucine
rich repeats (LRR). The majority of CD
associated mutations directly affect the
LRR, which is a motif common to
bacterial resistance R proteins in plants
and mammals, notably the Toll-like
receptor family,23 enabling recognition
of pathogen associated microbial pat-
terns (PAMPs). Following PAMP recog-
nition, the NOD2/CARD15 proteins
dimerise and an interaction with the
serine-threonine kinase RICK in the
cytosol occurs, triggering downstream
nuclear factor kB (NFkB) activation.20
The original expression studies had
suggested that NOD2/CARD15 was
expressed only in monocytes, and impli-
cated the protein as an intracellular
regulator of NFkB activity, sensitive to
bacterial lipopolysaccharide (LPS), com-
plementary to NOD1/CARD4.20
In recent months strong scientific
evidence has emerged to complement
initial observations. It is now clear that
NOD2/CARD15 expression occurs not
only in monocytes but may also be
induced in dendritic cells24 and intest-
inal epithelial cells.25 Furthermore, inde-
pendent data suggest that the minimal
bacterial motif recognised by NOD2/
CARD15 may not be LPS, as initially
suggested, but muramyl dipeptide
(MDP),26 27 a component of both Gram
negative and positive bacterial cell walls.
It has been a consistent and unex-
plained observation, if somewhat coun-
terintuitive, that both common and rare
CD associated variants of the NOD2/
CARD15 gene result in reduced NFkB
activity, although these data are from
transfection experiments of NOD2/
CARD15 gene constructs in embryonic
kidney cells.27 28 Conversely, the uncon-
trolled mucosal inflammation of
Crohn’s disease is characterised by
upregulation of NFkB activation.29
In 2003, Hisamatsu et al provided
perhaps the most elegant evidence to
date, that CARD15/NOD2 may function
as an antibacterial factor in CaCo2
intestinal epithelial cells.30 Cells stably
transfected with a wild-type CARD15/
NOD2 gene construct were able to
prevent invasion by Salmonella typhimur-
ium. This protective effect was lost in
cells transfected with gene constructs of
mutant CARD15/NOD2. In the same
issue of Gastroenterology, Rosenstiel et al
also demonstrated that NOD2/CARD15
expression in intestinal epithelial cells
might be upregulated by the proinflam-
matory cytokine tumour necrosis factor
a (TNF-a).25
Thus with NOD2/CARD15 identifica-
tion, the emphasis in studies of IBD
pathophysiology has shifted to investi-
gations of the innate immune response.
The story now develops further with
data that suggest that NOD2/CARD15
may be expressed in the Paneth cells of
the small intestine31, published in this
issue of Gut [see page 1591]. Ogura et al
have used the techniques of immuno-
histochemistry and reverse transcrip-
tion-polymerase chain reaction to
examine NOD2/CARD15 expression in
the ileal or colonic tissue from IBD
patients and controls. NOD2/CARD15
expression was found to be localised to
Paneth cells, within the ileum, or
metaplastic Paneth cells within the
colon. Indeed, in a parallel paper in
Gastroenterology, the same authors have
extended these observations using in
situ hybridisation and laser capture
microdissection.32 They demonstrated
that NOD2/CARD15 expression was
enriched in crypts, compared with villi,
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and cells expressing NOD2/CARD15 also
strongly expressed the proinflammatory
cytokine TNF-a, itself a potent stimulus
to NOD2/CARD15 expression. However,
NOD2/CARD15 expression was not a
feature of tissue macrophages in the
intestine.
Paneth cells are specialised epithelial
cells located mainly in the crypts of the
small intestine, in close proximity to
epithelial stem cells.33 Paneth cells
secrete antibacterial substances, initially
located in granules within the cytosol,
in response to prokaryotic rather than
eukaryotic pathogens.34 The main anti-
microbial factors secreted by the Paneth
cell include lysozyme, phospholipase A2,
trypsin,33 a-defensins,34 and angiogen-
ins.35 In the current studies, NOD2/
CARD15 expression was noted in close
proximity to the secretory granules.
Indeed, this close proximity prompts
speculation that NOD2/CARD15 may
be involved in degranulation and med-
iator released. It should be borne in
mind that Paneth cell degranulation
may be triggered not only by MDP but
also by other bacterial components.34
One may hypothesise that NOD2/
CARD15 might therefore be one of a
number of receptors involved in degran-
ulation but functional data would not
sustain the hypothesis that it is the sole
regulator of this function.
There is increasing interest in the
importance of members of the defensin
family of molecules in regulating innate
immune defences. The a-defensins,
which are expressed in Paneth cell
granules, are particularly pertinent to
the present studies. These cationic
cysteine rich peptides are synthesised
and stored as precursor proteins,36 and
in the mouse release requires lysis of the
prodefensin molecule by matrix metal-
loproteinase 7 (MMP7);37 in humans,
this lysis is thought to be mediated by a
Paneth cell specific trypsin.38 MMP7
deficient mice have decreased responses
to bacterial infections although they do
not exhibit chronic intestinal inflamma-
tion. It is intriguing to note recent
provocative data which suggest that
carriage of NOD2/CARD15 variants
may be associated with reduced a-
defensin release from Paneth cells in
response to bacterial cell wall compo-
nents (J Wehkamp, personal commu-
nication, Falk Symposium, Berlin,
2003). Could defective defensin release
by the Paneth cell provide the missing
link whereby reduced NOD2/CARD15
activity impair host defences to bacteria
and underlie persistent intestinal
inflammation? The interrelationship
between NOD2/CARD15 genotype,
NFkB activity, and Paneth cell secre-
tions clearly bears detailed examination.
It is worth mentioning in this context
that the b-defensin 2 gene contains an
NFkB binding site in the promoter
region,39 and although this defensin is
not a component of Paneth cell gran-
ules, it is overexpressed in colonic CD.40
In the present study in this issue of
Gut,31 Ogura et al were unable to find
consistent NOD2/CARD15 expression in
colonic mucosa. Only one patient with
colonic CD and concomitant Paneth cell
metaplasia showed NOD2/CARD15 col-
onic expression.32 This predominant ileal
localisation would explain the associa-
tion of NOD2/CARD15 mutations with
ileal disease. However, conflicting data
have recently been published,41 and the
issue remains to be resolved.
The functional role of the Paneth cell,
initially identified by Joseph Paneth in
Vienna in 1888, has remained unclear
for more than 100 years. The recent data
ever more strongly implicate the Paneth
cell as a contributory factor in the innate
immune response to bacteria. It is, of
course, of great interest to speculate that
this expression is critical in the patho-
genesis of chronic CD and further data
are eagerly awaited. Of particular inter-
est will be the phenotypic and morpho-
logical characteristics of transgenic
animals lacking the NOD2/CARD15
gene, and subsequent attempts to re-
introduce NOD2/CARD15 protein into
the Paneth cells of these animals.
Gut 2003;52:1533–1535
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Aspirin: still learning about the wonder
drug
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Aspirin, taken daily over at least one year, may exert
chemopreventive effects against the early stages of colorectal
carcinogenesis
P
reclinical, observational, and clin-
ical data consistently show that
non-steroidal anti-inflammatory
drugs (NSAIDs)—particularly aspirin—
reduce colorectal carcinogenesis.1 Scores
of animal studies show that NSAIDs
inhibit the development of colorectal
neoplasia across the spectrum of dis-
ease, ranging from aberrant crypt foci
(ACF) to cancer.2 Human data confirm
these findings with dozens of observa-
tional studies reporting 40–50% reduc-
tions in colorectal adenoma incidence,
cancer incidence, and cancer associated
mortality among aspirin users. The most
compelling data were published earlier
this year. Two randomised placebo con-
trolled trials conducted in patients at
moderate risk for colorectal cancer
reported that aspirin administered at
doses as low as 81–325 mg/day reduced
the development of adenomas by up to
35% after a few years of use.3 4 In one
trial, greater effects were seen against
more advanced lesions.3
Colorectal adenomas are established
as common non-obligate precursors of
colorectal cancer.5 Within the last dec-
ade, ACF have been identified in rodent
models of carcinogenesis, and have been
proposed as precursors of colorectal
adenomas and cancers.6 With the use
of recently developed high resolution/
magnifying endoscopes, researchers are
now making quantitative (for example,
number, size, crypt multiplicity) and
qualitative (for example, morphology)
real time in vivo assessments of ACF in
humans.7 ACF—or at least a subset of
them—may represent important risk
markers for adenoma-carcinoma devel-
opment in humans. They may also serve
as markers of chemopreventive res-
ponse. Thus although relatively little is
known about ACF and their relevance to
more advanced stages of colorectal
neoplasia in humans, they provide an
important and promising focus for
additional research.
In this issue of Gut, Shpitz and
colleagues8 weave together these two
investigational threads [see page 1598].
This group describes an association
between aspirin use and reduced ACF
prevalence and histopathological distri-
bution in ex vivo specimens obtained
from 194 patients with colorectal cancer.
Among patients who used aspirin for at
least one year, they observed a 47%
reduction in specimens harbouring ACF,
a 64–82% reduction in ACF per cm2 of
colorectal mucosa, and a 52% reduction
in dysplastic ACF. Although ACF reduc-
tions were observed in all anatomical
sites, the reductions tended to be more
dramatic in the distal colorectum. These
findings suggest that aspirin taken at
100 mg/day over at least one year may
exert chemopreventive effects against the
early stages of colorectal carcinogenesis.
While intriguing, these data must be
interpreted cautiously. Firstly, the study
groups differed with regard to variables
that may influence baseline risks for
colorectal neoplasia and/or aspirin use,
such as gender (males 84% v 52% in the
aspirin and control groups, respectively)
and age (aspirin users were much more
homogeneous than controls). The inves-
tigators do not address the potential
impact of these imbalances on the study
results, nor did they adjust for them in
the analysis. Because we have scant
information about ACF, these variables
may have confounded interpretations of
the effects of aspirin. In addition, the
investigators did not report study parti-
cipants’ dietary habits and their use of
concomitant medications. Preclinical
studies suggest that the latter two
exposures may modulate ACF and
therefore these limitations may be par-
ticularly important.9–12 Secondly, with-
out power estimates, it is impossible to
know whether the lack of statistical
significance for certain variables is true
or merely reflects the small sample size.
Finally, the selection of the study cohort
is not described in detail; therefore, the
generalisability of these study results is
uncertain.
Despite these limitations, the prelim-
inary findings of Shpitz and colleagues8
are stimulating and should prompt
additional investigations into whether
ACF reductions correlate with or predict
aspirin’s preventive efficacy against
more advanced stages of colorectal
neoplasia. These data contribute to a
growing body of research suggesting
that ACF might be used to identify the
preventive efficacy of investigational
agents against colorectal carcinogenesis.
Takayama et al originally reported
marked reductions in in vivo colorectal
ACF following 12 months of treatment
with sulindac.7 Both the Shpitz and
Takayama studies show that NSAIDs
reduce ACF burden after relatively brief
exposures. The data of Shpitz and
colleagues8 add another link to the
investigational chain by suggesting that
aspirin exerts greater effects against
more advanced (that is, dysplastic)
ACF. Evidence that aspirin modulates
both early and advanced ACF would
represent a major advance for the field
of chemoprevention research. Needless
to say, ultimate validation requires
linking NSAID induced reductions in
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ACF to reductions in colorectal adeno-
mas, cancer, and/or cancer associated
mortality.13 Nevertheless, this study
moves us closer to a distant but still
plausible goal of firmly establishing ACF
as meaningful short term markers for
cancer prevention research.
The study provides other important
insights as well. For example, the effects
of aspirin on early colorectal neoplasia
appear to be relative, not absolute.
While aspirin may have significantly
reduced the burden of ACF, all 59
aspirin responsive patients included in
the study still developed colorectal
cancer. Were ACF reduced to the same
extent—or perhaps to a greater extent—
among aspirin using patients who did
not develop cancer? Do reductions in
ACF predict for reductions in adenoma,
cancer, or cancer mortality, as suggested
by preclinical and observational data?
How might we best use or build upon
the data generated by Shpitz et al? This
provocative study leaves a trail of
important questions, the answers to
which may pave the way for future
successes in chemoprevention research.
Shpitz’s study8 also advances chemo-
prevention research through its novel
investigational design, by using patho-
logical specimens originally obtained to
diagnose or treat cancer, allowing for
parallel insights into earlier stages of
neoplasia. More than 75% of controls
had ACF, confirming how common
these preinvasive lesions are in patients
with colorectal cancer. If this situation is
typical, ACF may provide another mea-
sure by which the preventive efficacy of
agents might be quickly, albeit prelimi-
narily, assessed.
For example, ACF evaluations nested
within trials testing drug or dietary
interventions—including those intended
for other indications—might accelerate
agent development and prioritisation for
cancer prevention.14 This approach could
be readily implemented to efficiently test
some of the most commonly used drugs
or nutritional supplements in Western
populations, such as statins, PPAR ago-
nists, NSAIDs, and fibre, all of which may
have anticancer properties.9–12 15 With the
exception of NSAIDs, these have yet to
be tested in prospective, randomised,
controlled trials. Clearly, observational
data derived from ancillary endoscopic
assessments in single arm or random-
ised controlled trials might improve
the efficiency and speed of agent
identification and testing.
Aspirin has been used in various
forms to treat pain and inflammation
since as early as 500 BC. The array of
indications for aspirin has expanded to
include the prevention of myocardial
infarction and stroke, clinching its role
as the world’s first wonder drug.16
Aspirin now appears to be effective
against colorectal neoplasia; why and
how we still do not know. New insights
into carcinogenesis, such as those pro-
vided by Shpitz et al, will profoundly
alter our expectations for aspirin and
its potential to improve the public’s
health.
Gut 2003;52:1535–1536
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